Single-Cell Genome Sequencing Global Market Report 2024

The single-cell genome sequencing market size has grown rapidly in recent years. It will grow from $2.17 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 14.3%. The growth observed in the historical period can be attributed to the increased understanding of genetic heterogeneity, a rising demand for precision medicine, increased focus on cancer research, growth in the prevalence of infectious diseases, and increased healthcare spending.

The single-cell genome sequencing market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2028 at a compound annual growth rate (CAGR) of 14.6%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of autoimmune diseases, rising occurrences of neurological disorders, growing government initiatives and funding, the rise of contract research organizations (CROs), and increasing awareness of the potential of single-cell RNA sequencing (scRNA-seq). Key trends expected in the forecast period include advancements in single-cell sequencing technologies, the development of single-cell multi-omics technologies, collaborative initiatives to accelerate advancements, the introduction of innovative solutions, and partnerships among key players.

The anticipated rise in cancer prevalence is expected to drive the growth of the single-cell genome sequencing market in the future. Cancer, a diverse group of diseases characterized by uncontrolled cell growth, is a result of genetic changes affecting cell division and normal cellular functions. The disease is marked by genetic alterations, and single-cell genome sequencing proves invaluable in revealing these genetic changes at the individual cancer cell level. For example, in January 2023, the American Cancer Society reported approximately 1.9 million new cancer cases and 609,360 cancer-related deaths in the US in 2022. Predictions indicate a further increase, with an estimated 27.5 million new cancer cases and 16.3 million cancer deaths projected by 2040. Consequently, the rising incidence of cancer is expected to be a driving factor for the growth of the single-cell genome sequencing market.

The remarkable expansion of genomic data is a substantial contributor to the ongoing growth of the single-cell genome sequencing market. Genomic data encompasses information related to the structure and function of an organism's genome. The exponential increase in genomic data generated through single-cell sequencing opens up opportunities for data analysis, interpretation, and the development of bioinformatics tools, fostering market growth. As per a 2022 report from the National Human Genome Research Institute (NHGRI), the genomic data is projected to reach between 2 and 40 exabytes within the next decade. Hence, the rapid surge in genomic data is poised to propel the single-cell genome sequencing market.

Technological advancements emerge as a noteworthy trend gaining traction in the single-cell genome sequencing market. Leading companies in the sector are dedicated to developing technologically advanced solutions to enhance their market position. For instance, in May 2023, Mission Bio Inc., a US-based company specializing in single-cell multi-omics platforms, introduced the Tapestri Genome Editing Solution. This end-to-end product for genome editing analysis is expected to be a more effective analytical tool for developing next-generation gene-edited drugs, offering single-cell insights capable of impacting efficacy and safety.

Major players in the single-cell genome sequencing market are concentrating on the development of single-cell proteomics, a nascent discipline seeking to understand the diversity of protein expression within individual cells. Integrating single-cell genomics with proteomics techniques allows for studying the relationship between genomic information and protein expression at the single-cell level. For example, in October 2023, Proteome Sciences plc, a UK-based biotechnology company, launched SysQuant SCP, a single-cell proteomics commercial service. Leveraging the capabilities of its TMTpro isobaric labelling reagents, SysQuant SCP generates and analyzes quantitative mass spectrometry data to uncover subtle variations in individual cells and within subpopulations of the same primary cell type. This data is expected to advance our understanding of biological drivers of heterogeneity and evolution in disease contexts and therapy responses, providing new targets for personalized medicine.

In August 2021, Illumina Inc., a US-based company specializing in sequencing and array technologies, acquired GRAIL for an undisclosed amount. This strategic acquisition aligns with Illumina's mission to revolutionize healthcare, including combating the COVID-19 epidemic and assisting cancer patients in finding suitable treatments. GRAIL, a US-based biotechnology company, offers whole-genome sequencing, whole-genome methylation sequencing, and ultra-deep targeted sequencing.

Major companies operating in the single-cell genome sequencing market report are F Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., DH Life Sciences LLC., Becton Dickinson And Company (BD), Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Bio-Techne Corporation, BGI Genomics Co. Ltd., Fulgent Genetics Inc., 10x Genomics Inc., Promega Corporation, Takara Bio Inc., Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc., Standard BioTools Inc., Singleron Biotechnologies, MGI Tech Co. Ltd, GENEWIZ Inc., Mission Bio Inc., Zymo Research Corporation, Menarini Silicon Biosystems SpA, Novogene Co. Ltd., RareCyte Inc., Fluxion Biosciences Inc., Single Cell Discoveries B.V., Parse Biosciences Inc., BioSpyder Technologies Inc., SeqWell Inc.

North America was the largest region in the single-cell genome sequencing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell genome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single-cell genome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main types of single-cell genome sequencing include instruments and reagents. Instruments refer to specialized equipment or devices used to perform the various steps involved in the sequencing process. Various technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), quantitative polymerase chain reaction (qPCR), microarray, and multiple displacement amplification (MDA), are utilized in disease areas such as cancer, immunology, prenatal diagnosis, neurobiology, microbiology, and others. The applications encompass circulating cells, cell differentiation or reprogramming, genomic variation, subpopulation characterization, and others, serving academic research laboratories, biotechnology biopharmaceutical companies, clinics, and other related entities.

The single-cell genome sequencing market research report is one of a series of new reports that provides single-cell genome sequencing market statistics, including single-cell genome sequencing industry global market size, regional shares, competitors with a single-cell genome sequencing market share, detailed single-cell genome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the single-cell genome sequencing industry. This single-cell genome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single-cell genome sequencing market consists of revenues earned by entities by providing single-cell analysis, genetic heterogeneity study, identification of genomes of individual cells, and microbiomes and cancer study. The market value includes the value of related goods sold by the service provider or included within the service offering. The single-cell genome sequencing market also includes sales of single cell kit, DNA sequencing instruments and single-cell sequencing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.